AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01735357 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: EPA-rich triacylglycerol oil
Study NCT01735357 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - olive oil (BP specification)
Study NCT01735357 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: DHA-rich triacylglycerol oil
Study NCT02313818 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy-Cognitive Only
Description: Cognitive Processing Therapy-Cognitive Only (CPT-C) is an evidence-based form of Cognitive Behavioral Therapy (CBT) used to treat PTSD. CPT is a manualized program that focuses on challenging beliefs and assumptions related to the trauma, oneself, and the world. Individual sessions will be conducted twice weekly for 4-24 sessions; each session is 60 minutes.
Study NCT01727518 — intervention group
Intervention type: OTHER
Intervention: As the LEAD study is an observational cohort study, there is no intervention to report.
Description: As the LEAD study is an observational cohort study, there is no intervention to report.
Study NCT03117465 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: the experimental group
Description: Stroke hemiplegia patients are randomly assigned to the experimental group (scalp acupuncture + low frequency repetitive transcranial magnetic stimulation + routine rehabilitation treatment). All patients in the day of inpatient and the fourteenth day received DTI magnetic resonance examination twice to study the change in white matter fiber microstructure.
Study NCT03117465 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: the control group
Description: Stroke hemiplegia patients are randomly assigned to the control group (scalp acupuncture + routine rehabilitation treatment). All patients in the day of inpatient and the fourteenth day received DTI magnetic resonance examination twice to study the change in white matter fiber microstructure.
Study NCT03326089 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pulmonary rehabilitation
Description: Endurance training for 30 minutes, 3 times/week for 2 months followed by resistance training
Study NCT03326089 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Pulmonary rehabilitation
Description: Endurance training for 30 minutes, 3 times/week for 2 months followed by resistance training
Study NCT01749163 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Saline
Study NCT01749163 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GIP
Study NCT01749163 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GLP-1
Study NCT04228406 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GST-HG161
Description: There are 7 dose cohorts, including60mg, 150mg, 300mg, 450mg, 600mg, 750mg, 900mg QD in the dose escalation stage and GST-HG161 will be administered orally to patients once daily for each dose cohort. Recommended dose in the dose expansion stage will be determined by the results in the dose escalation stage .
Study NCT00578578 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: eicosapentaenoic acid (EPA),
Description: three capsules daily (1350 mg daily) of EPA for 8 weeks or three capsules daily placebo for 8 weeks
Study NCT00578578 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: eicosapentaenoic acid (EPA),
Description: three capsules daily (1350 mg daily) of EPA for 8 weeks or three capsules daily placebo for 8 weeks
Study NCT03000348 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cysteamine
Description: Oral Cysteamine Capsule
Study NCT03882671 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EpiTel Epilog
Description: EEG recording device
Study NCT03882671 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Empatica E4
Description: PPG, sweat level, temperature and accelerometry recording device
Study NCT03882671 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GENEActiv
Description: Temperature, light level and accelerometry recording device
Study NCT04861662 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Free gingival graft procedure
Description: Free gingival graft procedure applied to implants with KM\<2 mm to increase the width of keratinized mucosa surrounding them
Study NCT04176133 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entolimod
Description: Intramuscular (IM) single dose administration. Entolimod is provided as a sterile, clear, colorless or slightly yellow liquid for IM injection.
Study NCT03000348 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Oral Capsule
Description: Placebo Oral Capsule
Study NCT03000348 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Capsule
Description: Placebo Oral Capsule
Study NCT04281693 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Standard screening strategy
Description: The pharyngeal swab specimen was obtained and sent for NCIP RNA detection by individual testing.
Study NCT04281693 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: New screening strategy
Description: The pharyngeal swab specimen was obtained and sent for NCIP RNA detection by minipool testing.
Study NCT03112408 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Forward adaptation of reactive saccades
Description: Protocol of reactive saccade where the target is displaced in the same direction as the saccade in order to induce an adaptive increase of saccade amplitude ('forward adaptation')
Study NCT03112408 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Backward adaptation of reactive saccades
Description: Protocol of reactive saccade where the target is displaced in a direction opposite to the saccade in order to induce an adaptive decrease of saccade amplitude ('backward adaptation')
Study NCT03112408 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Execution of reactive saccades
Description: Control protocol of reactive saccade with no displacement of the saccadic target (controlling for non specific factors possibly involved in forward and backward adaptation conditions)
Study NCT03112408 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Generation of reactive saccades
Description: Control protocol of reactive saccade with no displacement of the saccadic target (controlling for non specific factors possibly involved in adaptation condition)
Study NCT00878553 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: tablet at bedtime
Study NCT00878553 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SKP-1041 (experimental formulation of zaleplon)
Description: tablet at bedtime
Study NCT00626015 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PEP-3-KLH conjugate vaccine
Description: Given intradermally
Study NCT00626015 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: daclizumab
Description: Given IV
Study NCT00123682 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Self-help
Description: Project staff send out self-help materials for smoking cessation
Study NCT01587625 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Study NCT01587625 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Study NCT03085771 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: desferal
Description: It is a blinded randomized cross-over study that investigates the efficacy of DFO (50mg/kg) given i.v before intermittent hypoxia (IH) to improve the cardiorespiratory and angiogenetic response in patients with diabetes.
Study NCT03085771 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Isotonic saline
Description: It is a blinded randomized cross-over study that investigates the efficacy of isotonic saline given i.v before intermittent hypoxia (IH) to improve the cardiorespiratory and angiogenetic response in patients with diabetes.
Study NCT03942003 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: rhomboid blocks
Description: Rhomboid nerve block was performed
Study NCT03942003 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PEC blocks
Description: PEC I-II blocks was performed
Study NCT03942003 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Control groups
Description: Infiltration analgesia was performed
Study NCT04231968 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK0529
Description: AK0529 capsule will be orally administered at the twice-daily dosing levels of 10 mg, 20 mg, or 40 mg for five days based on the patient's weight.
Study NCT04231968 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebo of AK0529
Description: The placebo capsule was made with the same smell and appearance as AK0529 but without the active ingredients and will be orally administered per the same treatment schedule as those in the experimental arm.
Study NCT02440854 — intervention group
Intervention type: DRUG
Intervention: afatinib
Description: Patients were treated as per the routine medical practice in terms of visit frequency, types of assessments performed and with adherence to the local prescribing requirements for afatinib.
Study NCT02503644 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IVA337
Description: Capsules of 200mg IVA337
Study NCT02503644 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Identical capsules without active substance
Study NCT04129775 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OTO-413
Description: Single intratympanic injection of Brain-Derived Neurotrophic Factor (BDNF)
Study NCT04129775 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single intratympanic injection of placebo
Study NCT04790097 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Moderately Hypofractionated Radiotherapy using Simultaneous In-Field Boost
Description: 78Gy in 30 fractions on FET-PET based target volumes;~60Gy in 30 fractions on 2cm margin from MRI based target volumes;~all patients will be treated with concomitant and adjuvant temozolomide
Study NCT02483572 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Functional Communication Training
Description: Functional communication training (FCT) is the most widely used treatment for severe destructive behavior that is maintained by social reinforcement, such as access to attention, tangible items, or escape from nonpreferred activities. Once clinicians determine the functional reinforcer for destructive behavior, the clinician can then teach the child an appropriate, functionally-equivalent response (e.g., exchanging a card to access parental attention) and the clinician would no longer provide the functional reinforcer for destructive behavior.
Study NCT03526055 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Algovita Spinal Cord Stimulation System
Description: The Algovita™ SCS system is indicated as an aid in the management of chronic intractable pain of the trunk and/or limbs, including unilateral or bilateral pain associated with failed back surgery syndrome, intractable low back pain and leg pain.
Study NCT04176133 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intramuscular (IM) single dose administration, no active ingredient. A matching placebo is provided as a sterile, clear, colorless to slightly yellow liquid for IM injection in prefilled vials that are identical in appearance to the vials containing active drug.
Study NCT03526055 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Algovita Spinal Cord Stimulation System
Description: The Algovita™ SCS system is indicated as an aid in the management of chronic intractable pain of the trunk and/or limbs, including unilateral or bilateral pain associated with failed back surgery syndrome, intractable low back pain and leg pain.
Study NCT04582565 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Decongestive lymphatic therapy (DLT)
Description: Manual lymphatic drainage
Study NCT04582565 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Study NCT02945696 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laparoscopic guided nerve blocks
Description: It is common to use ultrasound to define the correct plane for abdominal wall nerve blocks, however, the utilization of laparoscopy to identify this plane is a new intervention that is previously undescribed in children.
Study NCT02945696 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: Ropivacaine is a local anesthetic used to prevent pain during and after procedures. In this study, ropivacaine will be injected either directly at the port sites, or for a regional abdominal wall nerve block, either under ultrasound or laparoscopic guidance.
Study NCT00626015 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temozolomide
Description: Given by mouth.
Study NCT00626015 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: placebo
Description: Given IV
Study NCT00626015 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PEP-3-KLH
Description: Basiliximab 20 mg IV over 30 minutes with PEP-3-KLH vaccine # 1 only.
Study NCT03079076 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: 20 ml %0,25 bupivacaine bilaterally
Study NCT03079076 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: 2 ml saline subcutaneously bilaterally
Study NCT04931719 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: PRP+Artz group
Description: The patients in the PRP+Artz group received one intraarticular Artz injection (2.5 ml) followed consecutively by one intraarticular injection of PRP (3ml).
Study NCT04931719 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: PRP+Artz group
Description: The patients in the PRP+Artz group received one intraarticular Artz injection (2.5 ml) followed consecutively by one intraarticular injection of PRP (3ml).
Study NCT04931719 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: PRP+ HYAJOINT Plus group
Description: The patients in the PRP+HYAJOINT Plus group received one intraarticular HYAJOINT Plus injection (3ml) followed by one intraarticular injection of PRP (3ml).
Study NCT04931719 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: PRP+ HYAJOINT Plus group
Description: The patients in the PRP+HYAJOINT Plus group received one intraarticular HYAJOINT Plus injection (3ml) followed by one intraarticular injection of PRP (3ml).
Study NCT01380691 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2216684
Description: Administered orally
Study NCT01380691 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo-matching LY2216684
Description: Administered orally
Study NCT01380691 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo-matching alcoholic beverage
Description: Administered orally
Study NCT03194945 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CSII followed by Lina+MET
Description: short-term intensive CSII followed by Linagliptin 5mg qd and Metformin 0.5g bid for 48 weeks
Study NCT03194945 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CSII followed by Lina
Description: short-term intensive CSII followed by Linagliptin 5mg qd for 48 weeks
Study NCT03194945 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CSII followed by MET
Description: short-term intensive CSII followed by Metformin 0.5g bid for 48 weeks
Study NCT03194945 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CSII alone
Description: No OHA is given after short-term intensive CSII
Study NCT02360865 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Study NCT02360865 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Study NCT02801864 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Real tDCS
Description: Participants will receive tDCS at 1mA for 20min of the total three hours of intensive speech therapy time at the beginning of each session. Stimulation will be provided via an electrode using a Starstim device.
Study NCT02801864 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS
Description: Participants will receive tDCS at 1mA for 20min of the total three hours of intensive speech therapy time at the beginning of each session. Stimulation will be provided via an electrode using a Starstim device.
Study NCT02801864 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intensive Speech Therapy
Description: Participants will receive one hour of group therapy and two hours of individual therapy that will follow VNeST format. The purpose of therapy will be to have the client generate verbs and nouns in written and verbal form.
Study NCT02801864 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Intensive Speech Therapy
Description: Participants will receive one hour of group therapy and two hours of individual therapy that will follow VNeST format. The purpose of therapy will be to have the client generate verbs and nouns in written and verbal form.
Study NCT02109666 — intervention group
Intervention type: DRUG
Intervention: Abatacept
Study NCT00530998 — intervention group
Intervention type: PROCEDURE
Intervention: Transvaginal Appendectomy
Description: The appendix will be removed via an incision in the vagina.
Study NCT00530998 — intervention group
Intervention type: PROCEDURE
Intervention: Transvaginal Cholecystectomy
Description: The gallbladder will be removed via an incision in the vagina.
Study NCT02505477 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine
Description: N-acetylcysteine is a safe, widely available supplement currently FDA-approved for treatment of acetaminophen antidote and as a mucolytic. It has effects on glutamate in the brain via the NMDA receptor as well as the glutathione antioxidant system (it is a precursor to glutathione).
Study NCT02505477 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment as Usual
Description: Treatment for schizophrenia which may include medications, therapy, or other types of treatment as determined by the subject's VA or community psychiatrist or mental health treatment team
Study NCT02505477 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Treatment as Usual
Description: Treatment for schizophrenia which may include medications, therapy, or other types of treatment as determined by the subject's VA or community psychiatrist or mental health treatment team
Study NCT04063046 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: General anesthesia
Description: General anesthesia is induced with propofol (0.5-2mg / kg), remifentanil (4-8㎍ / kg / hr) and rocuronium (0.4 \~ 0.6 mg / kg) involving laryngeal mask(supraglottic airway device) insertion or endotracheal intubation. Anesthesia is maintained with 1.0-2.5% sevoflurane and remifentanil.
Study NCT04063046 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peripheral nerve block
Description: ultrasound-guided popliteal sciatic nerve block is performed
Study NCT02964546 — intervention group
Intervention type: OTHER
Intervention: Blood sample
Description: 2 additional tubes of blood samples are collected during a blood sample realized for the patient's care
Study NCT02238106 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salmeterol medium dose
Study NCT02238106 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salmeterol low dose
Study NCT02238106 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salmeterol high dose
Study NCT02238106 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Serevent® Diskus®
Study NCT02238106 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo HandiHaler®
Study NCT02238106 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo HandiHaler®
Study NCT02238106 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo HandiHaler®
Study NCT02238106 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Diskus®
Study NCT02238106 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Diskus®
Study NCT02238106 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Diskus®
Study NCT03253068 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus amurubicin
Description: Pembrolizumab 200mg/body plus amurubicin 40mg/m2, intravenous, every 3 weeks
Study NCT04198493 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP
Description: CPAP treatment every night plus conservative treatment for OSA: sleep hygiene and dietary counseling
Study NCT04198493 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CONSERVATIVE TREATMENT for OSA
Description: Conservative treatment for OSA: sleep hygiene and dietary counseling
Study NCT04198493 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CONSERVATIVE TREATMENT for OSA
Description: Conservative treatment for OSA: sleep hygiene and dietary counseling
Study NCT03428464 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Bicarbonate
Description: Participants will take ½ the daily dose of sodium bicarbonate in the morning and the other ½ in the evening.